Researchers at the Korea Institute of Science and Technology (KIST) have announced a new discovery in the fight against melanoma. The study, published in the journal Molecular Cancer, reveals a new mechanism behind drug resistance in melanoma and proposes potential strategies to overcome it.
Health Professionals
Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma
Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small retrospective case review showed.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
A melanoma diagnosis increases risk of a second primary melanoma regardless of race or ethnicity, a review of a government database showed.
Risk for Second Melanoma Up for Those With First Melanoma Diagnosis
WEDNESDAY, Oct. 9, 2024 (HealthDay News) — Patients with a first melanoma diagnosis have an increased risk for a second melanoma diagnosis, regardless of race and ethnicity, according to a research letter published online Oct. 9 in JAMA Dermatology.